Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Canopy Growth (CGC – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report).
Canopy Growth (CGC)
In a report released today, Nadine Sarwat from Bernstein maintained a Hold rating on Canopy Growth, with a price target of C$6.70. The company’s shares closed last Tuesday at $4.73, close to its 52-week low of $3.46.
According to TipRanks.com, Sarwat is a 3-star analyst with an average return of
Currently, the analyst consensus on Canopy Growth is a Moderate Sell with an average price target of $4.28, which is a -11.2% downside from current levels. In a report issued on January 26, TD Cowen also assigned a Hold rating to the stock.
See today’s best-performing stocks on TipRanks >>
Vertex Pharmaceuticals (VRTX)
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $450.00. The company’s shares closed last Tuesday at $448.03.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of
Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $402.31, implying a -6.4% downside from current levels. In a report issued on January 24, Cantor Fitzgerald also maintained a Buy rating on the stock with a $440.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CGC:
- Canopy Growth files to sell 16.32M shares of common stock for holders
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Largest borrow rate increases among liquid names
- Canopy Growth sells 8.16M units at $4.29 in private placement
- Canopy Growth shares higher after saying subscription pact terminated
